Antibodies are the fastest growing area of new drug development. There are more than 70 approved antibodies and hundreds under clinical testing. However, antibody therapies are costly and can have adverse side effects.
Abulus is a preclinical biotech company evaluating a proprietary antibody-based drug delivery platform that offers a cost-effective solution with increased efficacy and reduced adverse side effects.
To significantly improve outcomes for patients undergoing antibody therapies by developing a better and more cost-effective drug delivery technology.
The technology delivers antibodies accurately while extending the release time to disease sites for increased efficacy and reduced adverse side effects.
The antibody delivery technology is composed of a thermo-responsive biomaterial, immune tolerant elastin-like polypeptide (iTEP), which is safe, biocompatible, and does not induce an immune response.
The iTEP delivery platform is applicable to any antibody and can deliver multiple antibodies simultaneously, allowing combinations of multiple antibodies to treat disease more efficiently.
The iTEP platform can adjust the release rates and ratios of the delivered antibodies to give optimal therapeutic efficacy while reducing side effects.
The iTEP platform is a “plug-and- play” delivery platform that only needs a simple procedure of mixing iTEP and antibodies just ahead of injections, which takes only a few minutes. The iTEP platform maintains antibodies’ activity and integrity without chemically modifying antibodies.
The iTEP platform can be manufactured in large scale with high bench-to-bench consistency. The iTEP is prepared separately without involving any antibodies in its production and storage, which avoids the problem of instability or degradation of antibodies that occur in many current delivery platforms.
Previous preclinical research has demonstrated the safety and efficacy of the iTEP platform for antibody treatment. Three pipelines are to be explored in the future:
Combinatorial immunotherapy is more effective than single-agent therapy in cancer patients. The iTEP platform can deliver multiple combinations of antibody-based immunotherapies to solid tumors and prevent the diffusion of antibodies to other healthy tissues, improving therapeutic effects and reducing the toxicity.
Antibodies represent a significant market for the treatment of arthritis. The iTEP platform can retain therapeutic antibodies in joints for a prolonged period, more effectively relieving pain, inflammation, and other arthritis symptoms.
Nearly 40% of antibodies are given to patients through multiple and frequent subcutaneous injections. The iTEP platform can sustain the release of antibodies upon subcutaneous injection, reducing injection frequency and improving patient outcomes.
Copyright © 2021 Abulus - All Rights Reserved.